- Home
- NRXS vs GDTC Comparison
NRXS vs GDTC Comparison
Compare NRXS & GDTC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | NRXS | GDTC |
|---|---|---|
| Founded | 2011 | 2018 |
| Country | United States | Singapore |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 25.8M | 24.8M |
| IPO Year | 2023 | 2023 |
Fundamental Metrics
Financial Performance| Metric | NRXS | GDTC |
|---|---|---|
| Price | $3.90 | $1.55 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $8.00 | N/A |
| AVG Volume (30 Days) | ★ 854.7K | 37.7K |
| Earning Date | 11-10-2025 | 04-24-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $3,362,320.00 | $573,193.00 |
| Revenue This Year | $31.05 | $5.37 |
| Revenue Next Year | $137.61 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | 36.89 | ★ 63.03 |
| 52 Week Low | $1.33 | $1.38 |
| 52 Week High | $6.20 | $4.05 |
Technical Indicators
Market Signals| Indicator | NRXS | GDTC |
|---|---|---|
| Relative Strength Index (RSI) | 69.03 | 42.83 |
| Support Level | $2.63 | $1.49 |
| Resistance Level | $4.25 | $1.63 |
| Average True Range (ATR) | 0.34 | 0.13 |
| MACD | 0.13 | 0.00 |
| Stochastic Oscillator | 78.57 | 27.03 |
Price Performance
Historical ComparisonAbout NRXS Neuraxis Inc.
Neuraxis Inc is a growth stage company is engaged in developing neuromodulation therapies to address chronic and debilitating conditions in children. The company is dedicated to advancing the science with its' proprietary Percutaneous Electrical Nerve Field Stimulation (PENFS) technology. The company focuses on targeted therapies for the pediatric and adolescent population suffering from disorders of gut-brain interaction (DGBIs).
About GDTC CytoMed Therapeutics Limited
CytoMed Therapeutics Ltd is a pre-clinical biopharmaceutical company focused on harnessing its proprietary technologies to create novel cell-based immunotherapies for the treatment of human cancers. The company's segment include: the business of innate immune cell-based immunotherapy, pluripotent stem cell-based therapy and undertaking the research and development of immune cell and stem cell-based therapy; and the business of processing and banking of cells including cord blood stem cells, research and development on cord blood derived cell-based therapy. Geographically, the company operates in Singapore and Malaysia which is the majority revenue generator.